Half of our genome is made of transposons — snips of DNA that can move and copy themselves. But they’re more than parasites ...
Report: Nonprofit founded by Shas candidate for bereaved families diverted funds to yeshiva students
Millions of shekels in public funding awarded to a nonprofit founded by Shas Knesset candidate Dror Amos to assist bereaved ...
The Israel Defense Forces is advancing plans to publish its 47-minute compilation of footage of the Hamas-led October 7 ...
Explore how whole exome sequencing works, how capture design determines what is actually covered, and when whole genome sequencing is the better choice.
The 2026 AACR Cancer Progress Report highlights a wave of targeted therapies and companion diagnostics transforming precision cancer treatment.
Discover the top gene editing stocks to watch. Learn about this groundbreaking field and the companies leading advancements ...
Navtemadlin’s oral MDM2 approach offers disease-modifying potential in myelofibrosis, especially after poor JAK inhibitor response. Monotherapy, ruxolitinib add-on use and development across blood and ...
LUXTURNA’s one-time, durable therapy addresses high unmet need in inherited retinal disease. Opportunities include broader genetic testing and treatment access, outcome-based reimbursement, global ...
Revolution Medicines (RVMD) secured rapid FDA approval for RASONQUE, a first-in-class oral RAS(ON) inhibitor targeting ...
A large number of genomic and transcriptomic datasets have revealed valuable insights into the biology of autism spectrum disorder (ASD). Wang et al. produced a complementary resource by mapping 100 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results